Targets › ADRA1A
76 programs from 62 companies in 108 trials: 45 Phase 4, 24 Phase 3, 22 Phase 2, 17 Phase 1; Cardiovascular, Other, Neurology; next expected readout Nov 2026.
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1A binds the catecholamine ligands norepinephrine and epinephrine. (UniProt, P35348)
Open in Phaseline: the race on ADRA1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Chicago | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Shock | Dec 2026 |
| King's College Hospital NHS Trust | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhosis, Liver | Dec 2026 |
| Cairo University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Incidence of Post-spinal Hypotension | Dec 2026 |
| Mansoura University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Mansoura University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Mansoura University | Silodosin Alpha-1a adrenergic receptor antagonist | ADRA1A | Phase 4 | BPH (Benign Prostatic Hyperplasia) | Jan 2027 |
| Sohag University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| Sohag University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| University of Alberta | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoplegia | Mar 2027 |
| ARS Pharmaceuticals | Epinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic … | Apr 2027 |
| Icahn School of Medicine at Mount Sinai | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Labor | May 2027 |
| Beni-Suef University | Silodosin Alpha-1a adrenergic receptor antagonist | ADRA1A | Phase 4 | Acute Urinary Retention | May 2027 |
| Hospital Sirio-Libanes | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cancer | May 2027 |
| James J. Peters Veterans Affairs Medical Center | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension | Jun 2027 |
| James J. Peters Veterans Affairs Medical Center | Midodrine Hydrochloride Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension | Jun 2027 |
| University of California, Davis | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension and Shock | Jun 2027 |
| Seoul National University Hospital | Phenoxybenzamine Adrenergic receptor alpha antagonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 4 | Pheochromocytoma | Aug 2027 |
| Aarhus University Hospital | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Intracerebral Haemorrhage | Sep 2027 |
| University of Alberta | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Vasoconstriction | Dec 2027 |
| University of Alberta | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoconstriction | Dec 2027 |
| Atlantic Health System | Silodosin Alpha-1a adrenergic receptor antagonist | ADRA1A | Phase 4 | Multiple Sclerosis | Mar 2028 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhotic Cardiomyopathy | Jan 2029 |
| Taipei Veterans General Hospital, Taiwan | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Hepatocellular Carcinoma (HCC); Cirrhosis | Oct 2030 |
| University of Rochester | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Heart Failure With Reduced Ejection Fraction (HFrEF) | Jun 2031 |
| Chinese University of Hong Kong | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Portal Hypertension | Jul 2031 |
| Bispebjerg Hospital | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Acute Myocardial Infarction | Dec 2035 |
| Dalian Municipal Central Hospital | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Nebraska Methodist Health System | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Postpartum Preeclampsia | – |
| Tunis University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Sepsis, Severe | – |
| Dalian Municipal Central Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Hassan II University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Section Complications | – |
| Dalian Municipal Central Hospital | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension Drug-Induced | – |
| Rawalpindi Medical College | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Phenylephrine | – |
| Hassan II University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Cesarean Section Complications | – |
| NHS Greater Glasgow and Clyde | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Sepsis | Nov 2026 |
| Odense University Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Shock | Dec 2026 |
| VA Office of Research and Development | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Posttraumatic Stress Disorder | Dec 2026 |
| Bir Hospital | Tamsulosin Hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Ureteral Stent-Related Symptom | Dec 2026 |
| Penang Hospital, Malaysia | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Stent Related Symptoms | May 2027 |
| Jagiellonian University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Blood Pressure Management | Jun 2027 |
| CHU de Quebec-Universite Laval | Tamsulosin hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Urinary Retention | Jul 2027 |
| Hospital do Coracao | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Septic Shock | Aug 2027 |
| Opus Genetics | Phentolamine Ophthalmic Solution 0.75% Non-selective alpha-1 and alpha-2 adrenergic antagonist | ADRA1A, ADRA1B, ADRA1D, ADRA2A | Phase 3 | Vision Loss Night; Insulin Resistance | Aug 2027 |
| University Hospital, Bordeaux | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Stroke, Acute | Aug 2027 |
| Loma Linda University | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Postpartum Complication | Dec 2027 |
| University of Minnesota | Qsymia Phentermine/topiramate extended-release combination; sympathomimetic amine and carbonic an | ADRA1A, HTR2C | Phase 3 | Healthy Volunteers | Oct 2030 |
| University College, London | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Parkinsons Disease (PD) | May 2031 |
| SWOG Cancer Research Network | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | Jun 2031 |
| Ain Shams University | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | – |
| University of Turin, Italy | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Critical Illness | – |
| Cairo University | OraVerse (phentolamine mesylate) Alpha-adrenergic antagonist and vasodilator that reverses local anesthetic effects by bloc | ADRA1A, ADRA1B | Phase 3 | Soft Tissue Injuries | – |
| Santen SAS | Oxymetazoline (STN1013800) Adrenergic receptor alpha agonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 3 | Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction | – |
| Brown University | Doxazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2026 |
| University of Wisconsin, Madison | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Magnetic Resonance Imaging | May 2027 |
| University of Aarhus | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Hypotension | Dec 2027 |
| University of Aarhus | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Hypotension | Dec 2027 |
| Giuseppe Cullaro, MD | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Acute Kidney Injury | Dec 2027 |
| Ottawa Heart Institute Research Corporation | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Heart Failure With Reduced Ejection Fraction | Jun 2028 |
| Sherief Abd-Elsalam | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | Esophageal Varices | Dec 2030 |
| Michele Tagliati, MD | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | REM Sleep Behavior Disorder; Symptomatic Parkinson Disease | – |
| Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Xylometazoline nasal drops 0.1% Alpha-1 and alpha-2 adrenergic agonist for vasoconstriction | ADRA1A, ADRA1B, ADRA2A | Phase 2 | Nasal Bleeding | – |
| Kingston Health Sciences Centre | norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Shock | – |
| Kingston Health Sciences Centre | phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Shock | – |
| Geriatric Hospital of Nanjing Medical University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Urolithiasis | Dec 2026 |
| University of Alabama at Birmingham | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension in Pregnancy | Dec 2026 |
| Applied Biology | DA-020 Topical alpha-1 adrenergic agonist | ADRA1A | Phase 1 | Chemotherapy Induced Alopecia | Feb 2027 |
| University of Manitoba | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Blood Loss, Surgical | Jun 2028 |
| Stephen G. Kaler | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Menkes Disease | Jun 2030 |
| Brigham and Women's Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension | – |
| Inder Paul Singh, M.D. | Omidria Intracameral phenylephrine and ketorolac combination solution | ADRA1A | Phase 1 | Cataract | – |
| Montefiore Medical Center | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Mitral Regurgitation | – |
| Berlin-Chemie AG Menarini Group | Tamsulosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis … | – |
| University of Iowa | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy | – |
| Mansoura University | carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 1 | TBI Traumatic Brain Injury | – |
Shock (5) Hypotension (4) REM Sleep Behavior Disorder (3) Hypotension Drug-Induced (3) Cesarean Delivery (2) Healthy Volunteers (2) BPH (Benign Prostatic Hyperplasia) (2) Acute Urinary Retention (2) Stent Related Symptoms (2) Urinary Retention (2) Cardiotoxicity (2) Vasoconstriction (2)
small molecule (72), protein or peptide (1)
Mansoura University (4) University of Alberta (3) Dalian Municipal Central Hospital (3) Cedars-Sinai Medical Center (2) James J. Peters Veterans Affairs Medical Center (2) Cairo University (2) Sohag University (2) University of Aarhus (2) Hassan II University (2) Kingston Health Sciences Centre (2) Nebraska Methodist Health System (1) University College, London (1) Applied Biology (1) Seoul National University Hospital (1) Bir Hospital (1) Icahn School of Medicine at Mount Sinai (1) Hospital do Coracao (1) Inder Paul Singh, M.D. (1) Tunis University (1) Santen SAS (1)
ADRB1 (42) ADRB2 (42) ADRA1D (39) ADRA2A (33) ADRA2C (31) ADRA1B (28) ADRB3 (13) HTR2C (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.